• Publications
  • Influence
Diagnosis, management, and treatment of hepatitis C: An update
This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
These guidelines review what treatment for genotype 1 chronic HCV infection is now regarded as optimal, but they do not address the issue of prioritization of patient selection for treatment or of treatment of special patient populations. Expand
Diagnosis, management, and treatment of hepatitis C
Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Expand
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.
These investigations demonstrate that both lactulose and neomycin-sorbitol are effective in the treatment of chronic portal-systemic encephalopathy. Expand
Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring
Although ALT is useful for detecting acute and chronic hepatic injury, it is not related to severity of acute Hepatitis B and C and only weakly related to severe severity of chronic hepatics injury. Expand
Natural history of chronic hepatitis C
  • L. Seeff
  • Medicine
  • Hepatology
  • 1 November 2002
Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly, so that at least 20% of chronically infected adults develop cirrhosis within 20 years. Expand
Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests.
The international normalized ratio should not be the sole method for reporting results of prothrombin time in liver disease; additional research is needed to determine the reporting mechanism that best correlates with functional impairment. Expand
Hepatitis C and renal disease: an update.
There are significant needs in both basic and clinical research in the pathogenesis, natural history, prevention, and therapy for hepatitis C in patients with renal disease, particularly among patients with end-stage renal disease and renal transplants. Expand
A report of a case and review of the literature
It is suggested that the development of unexplained fever within 1 month of quinidine administration should lead to consideration of possible hepatotox­ icity. Expand
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
It was found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort, and baseline clinical and laboratory features predicted risk for HCC. Expand